FDA: First Generic Version of Cancer Drug Doxil Approved

Monday, February 4, 2013 (Last Updated: 02/05/2013)

MONDAY, Feb. 4 (HealthDay News) -- The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages of the brand-name medication.

Doxil is on the agency's drug shortage list. The list empowers the FDA's Office of Generic Drugs to grant priority review to generic equivalents, the agency said Monday in a news release.

Noting that generics were of the same quality and strength as the original drugs, the FDA said: "Generic manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs."

Generic Doxil will be produced by Sun Pharma Global FZE in 20 milligram and 50 milligram vials. The brand-name drug is produced by Janssen Pharmaceuticals.

More Information

Specialties Radiology
Internal Medicine
Family Practice
Hematology & Oncology
OBGYN & Women's Health

Health News Copyright © 2013 HealthDay. All rights reserved.


Webucation: Introduction to Proton Therapy for Adult Cancers
by OncoLink Editorial Team
January 30, 2015

Medicinal Mushrooms – Support and Safety During Breast Cancer
by The 4Wholeness Team
September 29, 2015